JP2016507543A - 小胞を含む医薬組成物 - Google Patents

小胞を含む医薬組成物 Download PDF

Info

Publication number
JP2016507543A
JP2016507543A JP2015556499A JP2015556499A JP2016507543A JP 2016507543 A JP2016507543 A JP 2016507543A JP 2015556499 A JP2015556499 A JP 2015556499A JP 2015556499 A JP2015556499 A JP 2015556499A JP 2016507543 A JP2016507543 A JP 2016507543A
Authority
JP
Japan
Prior art keywords
vesicles
animal
vesicle
composition
omv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015556499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507543A5 (https=
Inventor
グランディ，グイド
グランディ，アルベルト
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
エクスターノーティクス エスピーエー
エクスターノーティクス エスピーエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, エクスターノーティクス エスピーエー, エクスターノーティクス エスピーエー filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2016507543A publication Critical patent/JP2016507543A/ja
Publication of JP2016507543A5 publication Critical patent/JP2016507543A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
JP2015556499A 2013-02-07 2014-02-06 小胞を含む医薬組成物 Pending JP2016507543A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13154463 2013-02-07
EP13154463.7 2013-02-07
PCT/EP2014/052370 WO2014122232A1 (en) 2013-02-07 2014-02-06 Pharmaceutical compositions comprising vesicles

Publications (2)

Publication Number Publication Date
JP2016507543A true JP2016507543A (ja) 2016-03-10
JP2016507543A5 JP2016507543A5 (https=) 2017-03-09

Family

ID=47681775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015556499A Pending JP2016507543A (ja) 2013-02-07 2014-02-06 小胞を含む医薬組成物

Country Status (7)

Country Link
US (1) US20160120818A1 (https=)
EP (1) EP2953620A1 (https=)
JP (1) JP2016507543A (https=)
CN (1) CN105163724A (https=)
BR (1) BR112015018877A2 (https=)
CA (1) CA2900454A1 (https=)
WO (1) WO2014122232A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109243B2 (en) 2017-09-08 2024-10-08 Evelo Biosciences, Inc. Bacterial extracellular vesicles
JP2025523867A (ja) * 2022-07-13 2025-07-25 イファ ユニバーシティ－インダストリー コラボレーション ファウンデーション 抗原タンパク質または該タンパク質をコードする遺伝子を有する細胞外小胞およびその用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037503B1 (ru) * 2014-01-21 2021-04-05 Анджариум Байосайенсиз Аг Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства
CN106999444B (zh) * 2014-10-03 2023-12-12 安吉尼科分子传输公司 完整的细菌衍生的囊泡对小分子化合物的增强装载
US20190091307A1 (en) * 2016-03-03 2019-03-28 Institut Gustave Roussy Ptps-based vaccines against cancer
EP3563835A4 (en) * 2016-12-29 2020-12-30 Korea Institute of Science and Technology NEW EXOSOME-BASED ANTI-CANCER AGENT
BR102018008194A2 (pt) * 2018-04-24 2020-07-07 Universidade De São Paulo - Usp. kit farmacêutico e seus usos
WO2019210189A1 (en) * 2018-04-26 2019-10-31 University Of Louisville Research Foundation, Inc. Edible plant exosome-like nanovectors for vaccination
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020146390A1 (en) * 2019-01-09 2020-07-16 Exocure Biosciences, Inc. Bacteria-derived vesicles and uses thereof
CN110367202B (zh) * 2019-06-20 2021-11-02 广东医科大学附属医院 一种肠菌外膜囊泡在制备痴呆动物模型中的应用
US20220378902A1 (en) * 2019-08-22 2022-12-01 Sichuan University Bacterial membrane vesicles, and separation and preparation system and method therefor
EP4013392B1 (en) 2019-09-13 2026-04-29 Exocure Sweden AB Use of ghost nanovesicles as therapeutics
CN111521826A (zh) * 2020-05-21 2020-08-11 江海松 外周血外泌体中Notch3蛋白作为分子标记的应用及一种检测试剂盒
WO2022154149A1 (ko) * 2021-01-14 2022-07-21 (주)엑솔런스 세포외소포체를 이용한 백신 조성물
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
CN115350161B (zh) * 2022-08-19 2024-04-16 沈阳药科大学 基于工程化益生菌外膜囊泡包被纳米酶递送系统及其制备方法和应用
CN117065041B (zh) * 2023-04-04 2024-02-27 山东大学 一种包被载药脂质纳米粒的外膜囊泡及其制备方法和应用
CN120789140B (zh) * 2025-09-12 2026-04-10 湖北医药学院 一种治疗结肠炎的联合用药物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514388A (ja) * 2001-12-17 2005-05-19 ヘルス プロテクション エージェンシー グラム陰性菌由来の外膜小胞およびワクチンとしての使用
JP2011513217A (ja) * 2008-02-22 2011-04-28 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） 間葉系幹細胞粒子

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU762369B2 (en) 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
PT2289545T (pt) * 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
EP1524991A1 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
EP1718338B1 (en) * 2004-02-02 2015-05-06 EnGeneIC Molecular Delivery Pty Ltd. Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
JP5667180B2 (ja) * 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514388A (ja) * 2001-12-17 2005-05-19 ヘルス プロテクション エージェンシー グラム陰性菌由来の外膜小胞およびワクチンとしての使用
JP2011513217A (ja) * 2008-02-22 2011-04-28 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） 間葉系幹細胞粒子

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLINICAL AND DEVELOPMENTAL IMMUNOLOGY, 2011, ARTICLE ID 842849, JPN6017044104, ISSN: 0003835929 *
HUMAN VACCINES & IMMUNOTHERAPEUTICS, JULY 2012, P.953-955, JPN6017044101, ISSN: 0003835926 *
PNAS, 2010, VOL.107, NO.7, P.3099-3104, JPN6017044102, ISSN: 0003835927 *
VACCINE, 2011, VOL.29, P.8293-8301, JPN6017044103, ISSN: 0003835928 *
WOLFERS JOSEPH, NATURE MEDICINE, vol. V7 N3, JPN5016001856, 1 March 2001 (2001-03-01), US, pages 297 - 303, ISSN: 0003835930 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109243B2 (en) 2017-09-08 2024-10-08 Evelo Biosciences, Inc. Bacterial extracellular vesicles
JP2025523867A (ja) * 2022-07-13 2025-07-25 イファ ユニバーシティ－インダストリー コラボレーション ファウンデーション 抗原タンパク質または該タンパク質をコードする遺伝子を有する細胞外小胞およびその用途

Also Published As

Publication number Publication date
US20160120818A1 (en) 2016-05-05
WO2014122232A1 (en) 2014-08-14
EP2953620A1 (en) 2015-12-16
BR112015018877A2 (pt) 2017-08-22
CN105163724A (zh) 2015-12-16
CA2900454A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
JP2016507543A (ja) 小胞を含む医薬組成物
Zhu et al. Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity
JP7244124B2 (ja) 生体高分子薬を送達するための組成物及び方法
Azmi et al. Recent progress in adjuvant discovery for peptide-based subunit vaccines
Shariat et al. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer
Altin et al. Liposomal vaccines—targeting the delivery of antigen
TWI449534B (zh) 利用陽離子性脂質之對映異構體刺激免疫反應
US20200405835A1 (en) Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypetides and immunogenic compositions thereof
EP3672625B1 (en) Synthetic vaccine
JP2014043459A (ja) Ｔ細胞応答の増強方法
US11638753B2 (en) Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EA034702B1 (ru) Липосомные композиции
Granadillo et al. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice
ES2342606T3 (es) Blanco in vivo de celulas dentriticas.
JP4210519B2 (ja) 低免疫原性抗原の免疫原性を増強する医薬組成物
Moore et al. Injectable, ribbon-like microconfetti biopolymer platform for vaccine applications
JPWO2015079952A1 (ja) アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法
Wang et al. A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells
Blom et al. Virosome-bound antigen enhances DC-dependent specific CD4+ T cell stimulation, inducing a Th1 and Treg profile in vitro
White et al. Immunogenicity of Liposomes Containing Lipid Core Peptides and the Adjuvant Quil A: White et al.
Karuturi et al. Encapsulation of an EP67-conjugated CTL peptide vaccine in nanoscale biodegradable particles increases the efficacy of respiratory immunization and affects the magnitude and memory subsets of vaccine-generated mucosal and systemic CD8+ T cells in a diameter-dependent manner
Shen et al. Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact
Kuai et al. Lipid-based nanoparticles for vaccine applications
JPWO2016194685A1 (ja) アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物
US8003093B2 (en) B cell-based vaccine loaded with the ligand of natural killer T cell and antigen

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180717